ATE153536T1 - Hiv-induzierte synzytien blockierender anti-cd-4- antikörper - Google Patents

Hiv-induzierte synzytien blockierender anti-cd-4- antikörper

Info

Publication number
ATE153536T1
ATE153536T1 AT92903295T AT92903295T ATE153536T1 AT E153536 T1 ATE153536 T1 AT E153536T1 AT 92903295 T AT92903295 T AT 92903295T AT 92903295 T AT92903295 T AT 92903295T AT E153536 T1 ATE153536 T1 AT E153536T1
Authority
AT
Austria
Prior art keywords
synzytia
hiv
antibodies
induced
blocking anti
Prior art date
Application number
AT92903295T
Other languages
German (de)
English (en)
Inventor
Linda C Burkly
Patricia L Chisholm
David W Thomas
Margaret D Rosa
Joseph J Rosa
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE153536T1 publication Critical patent/ATE153536T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92903295T 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4- antikörper ATE153536T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61854290A 1990-11-27 1990-11-27

Publications (1)

Publication Number Publication Date
ATE153536T1 true ATE153536T1 (de) 1997-06-15

Family

ID=24478147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903295T ATE153536T1 (de) 1990-11-27 1991-11-27 Hiv-induzierte synzytien blockierender anti-cd-4- antikörper

Country Status (12)

Country Link
US (1) US5871732A (enExample)
EP (1) EP0512112B1 (enExample)
JP (5) JPH05505112A (enExample)
AT (1) ATE153536T1 (enExample)
AU (1) AU662891B2 (enExample)
CA (1) CA2073031C (enExample)
DE (1) DE69126301T2 (enExample)
DK (1) DK0512112T3 (enExample)
ES (1) ES2101834T3 (enExample)
GR (1) GR3024274T3 (enExample)
OA (1) OA10079A (enExample)
WO (1) WO1992009305A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651970A (en) * 1993-03-19 1997-07-29 Allen; Allen D. Method for inhibiting disease associated with the human immunodeficiency virus through the use of monoclonal antibodies directed against anti-self cytotoxic T-lymphocytes or their lytics
DE4435950A1 (de) * 1994-10-07 1996-04-11 Hoechst Ag Copolymerisate mit cyclischen oder polycyclischen Monomeren mit einer speziellen Isomerenverteilung und deren Einsatz in Beschichtungsmitteln
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
AU3044697A (en) * 1997-06-24 1999-01-04 Norman Godin A composition for specific immunoprotection and method for obtaining said comp osition
US6420545B1 (en) * 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
CA2382161A1 (en) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies
WO2001043779A2 (en) * 1999-12-16 2001-06-21 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
AU2003299085B2 (en) * 2002-09-27 2008-04-10 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008019817A1 (en) * 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
TW200902544A (en) * 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US20130195881A1 (en) 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
SG190598A1 (en) * 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
KR20100135808A (ko) * 2008-03-13 2010-12-27 바이오테스트 아게 질병 치료제
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
DK2341937T3 (en) * 2008-09-29 2015-02-09 Biotest Ag Composition for the treatment of a disease
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
CN102321653B (zh) * 2011-07-18 2013-11-20 清华大学 人鼠嵌合型cd4质粒及其多抗在抑制hiv感染中的应用
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JP6408487B2 (ja) 2012-12-18 2018-10-24 ザ ロックフェラー ユニバーシティ Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3194442A4 (en) 2014-09-16 2018-05-23 UBI IP Holdings Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10858760B2 (en) 2015-06-01 2020-12-08 Medigene Immunotherapies Gmbh T cell receptor library
JP2018517711A (ja) * 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー 細胞表面タンパク質に対する抗体を作製する方法
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
BR112018012826A2 (pt) 2015-12-23 2018-12-04 Medigene Immunotherapies Gmbh método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
KR20190071677A (ko) 2016-08-13 2019-06-24 유나이티드 바이오파마, 인크. Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화
CN112175087B (zh) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
WO2021034913A1 (en) * 2019-08-19 2021-02-25 The Rockefeller University Engineering ph-dependent antigen binding activity into anti-hiv antibodies with improved pharmacokinetics
WO2021062546A1 (en) * 2019-10-01 2021-04-08 Taimed Biologics Inc. Use of ibalizumab for the treatment of hiv-2 infection
CN112500491B (zh) 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
EP4622631A1 (en) 2022-11-23 2025-10-01 University of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN117659192A (zh) * 2023-10-19 2024-03-08 深圳市福元生物科技有限公司 Cd4纳米抗体的制备及其应用
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515895A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing monoclonal antibody to human helper T cells
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4652447A (en) * 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4653020A (en) * 1983-10-17 1987-03-24 International Business Machines Corporation Display of multiple data windows in a multi-tasking system
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
WO1989001940A1 (en) * 1987-09-04 1989-03-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
US4908203A (en) * 1987-09-09 1990-03-13 Johnson & Johnson Method for inducing HIV neutralizing antibodies using an internal image idiotope
AU631357B2 (en) * 1987-10-14 1992-11-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The New anti-receptor peptides and therapeutic agents
WO1990004978A1 (en) * 1988-11-01 1990-05-17 Becton Dickinson And Company Method of directing immune response to a viral binding site
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies

Also Published As

Publication number Publication date
JP2007175055A (ja) 2007-07-12
US5871732A (en) 1999-02-16
CA2073031C (en) 2002-10-01
AU9154391A (en) 1992-06-25
JP2002356499A (ja) 2002-12-13
ES2101834T3 (es) 1997-07-16
AU662891B2 (en) 1995-09-21
DE69126301D1 (de) 1997-07-03
DE69126301T2 (de) 1998-01-02
EP0512112B1 (en) 1997-05-28
CA2073031A1 (en) 1992-05-28
WO1992009305A1 (en) 1992-06-11
HK1007686A1 (en) 1999-04-23
DK0512112T3 (da) 1997-09-29
JP2007151556A (ja) 2007-06-21
JPH05505112A (ja) 1993-08-05
EP0512112A1 (en) 1992-11-11
JP2005041859A (ja) 2005-02-17
JP4642035B2 (ja) 2011-03-02
OA10079A (en) 1996-12-18
GR3024274T3 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
ATE153536T1 (de) Hiv-induzierte synzytien blockierender anti-cd-4- antikörper
ATE86636T1 (de) F antigene vom menschlichen immunodefizienz-virus und deren verwendungen.
Ross et al. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
TR199801722T2 (xx) Peptit imm�nojenler.
DK0726758T3 (da) Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
CA2091263A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
Okamoto et al. Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432
DK0494294T3 (da) Bakterielle stressproteiner
DK1025849T3 (da) Fremgangsmåder til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-antigener
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
JO1671B1 (en) New ways to diagnose tuberculosis
EP0252064A3 (en) Preparations active against pseudomonas aeruginosa infections, and process for their preparation
Öberg et al. The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors
ATE142262T1 (de) Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
GR3024670T3 (en) Induction of protection against viral infection
Panem et al. Renal deposition of alpha interferon in systemic lupus erythematosus
ATE239502T1 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten
WO1991018618A3 (en) Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
PRÜMMER et al. Anti-interferon-γ antibodies in a patient undergoing interferon-γ treatment for systemic mastocytosis
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
Chen et al. The immunosuppressive peptide of HIV-1 gp41 like human type I interferons up-regulates MHC class I expression on H9 and U937 cells
Tyring et al. Antiviral action of murine interferons on heterologous cells
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time